Voxelotor (GBT440) produces interference in measurements of hemoglobin S.
作者信息
Rutherford Nicola J, Thoren Katie L, Shajani-Yi Zahra, Colby Jennifer M
机构信息
Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN, United States.
Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
出版信息
Clin Chim Acta. 2018 Jul;482:57-59. doi: 10.1016/j.cca.2018.03.032. Epub 2018 Mar 27.
Abstract
摘要
相似文献
1
Voxelotor (GBT440) produces interference in measurements of hemoglobin S.伏洛托（GBT440）会干扰血红蛋白S的测量。
Clin Chim Acta. 2018 Jul;482:57-59. doi: 10.1016/j.cca.2018.03.032. Epub 2018 Mar 27.
2
A "Split" Hemoglobin S Peak.一个“分裂”的血红蛋白S峰。
Clin Chem. 2020 Sep 1;66(9):1250-1251. doi: 10.1093/clinchem/hvaa135.
3
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.一项针对镰状细胞病患者的 voxotor 的 3 期随机试验。
N Engl J Med. 2019 Aug 8;381(6):509-519. doi: 10.1056/NEJMoa1903212. Epub 2019 Jun 14.
4
Two drugs for sickle cell disease.两种用于治疗镰状细胞病的药物。
Med Lett Drugs Ther. 2020 Apr 6;62(1595):51-52.
5
Voxelotor Treatment Interferes With Quantitative and Qualitative Hemoglobin Variant Analysis in Multiple Sickle Cell Disease Genotypes.Voxelotor 治疗会干扰多种镰状细胞病基因型中定量和定性血红蛋白变体分析。
Am J Clin Pathol. 2020 Oct 13;154(5):627-634. doi: 10.1093/ajcp/aqaa067.
6
How do we monitor hemoglobin S in patients who undergo red blood cell exchange and take voxelotor?我们如何监测接受红细胞置换并服用伏洛妥珠单抗的患者的血红蛋白S？
Transfusion. 2021 Jun;61(6):1680-1683. doi: 10.1111/trf.16405. Epub 2021 Apr 20.
7
Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin.通过提高血红蛋白的氧亲和力来治疗镰状细胞病。
Blood. 2021 Sep 30;138(13):1172-1181. doi: 10.1182/blood.2021012070.
8
Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease.在健康成年人和镰状细胞病患者中 voxotor（GBT440）的药代动力学和药效学。
Br J Clin Pharmacol. 2019 Jun;85(6):1290-1302. doi: 10.1111/bcp.13896. Epub 2019 Mar 31.
9
Interactions of an Anti-Sickling Drug with Hemoglobin in Red Blood Cells from a Patient with Sickle Cell Anemia.抗镰状细胞药物与镰状细胞贫血患者红细胞中血红蛋白的相互作用。
Bioconjug Chem. 2019 Mar 20;30(3):568-571. doi: 10.1021/acs.bioconjchem.9b00130. Epub 2019 Feb 28.
10
Voxelotor: A Novel Treatment for Sickle Cell Disease.伏打诺他：治疗镰状细胞病的新方法。
Ann Pharmacother. 2021 Feb;55(2):240-245. doi: 10.1177/1060028020943059. Epub 2020 Jul 16.
引用本文的文献
1
Impact of Voxelotor on Red Blood Cell Exchange Therapeutic Procedures: Evaluation of Multi-Institutional Procedure Data.羟基脲对红细胞置换治疗程序的影响：多机构程序数据评估
J Clin Apher. 2025 Jun;40(3):e70033. doi: 10.1002/jca.70033.
2
Newer Modalities and Updates in the Management of Sickle Cell Disease: A Systematic Review.镰状细胞病管理中的新型治疗方法与进展：一项系统综述
J Blood Med. 2024 Sep 12;15:435-447. doi: 10.2147/JBM.S477507. eCollection 2024.
3
Concentration of voxelotor in sickle cell disease can be estimated using electrophoresis and high-performance liquid chromatography.可使用电泳和高效液相色谱法估计镰状细胞病患者中伏洛托的浓度。
Am J Clin Pathol. 2024 Sep 3;162(3):297-301. doi: 10.1093/ajcp/aqae042.
4
Influence of Voxelotor-hemoglobin complexes in the estimation of hemoglobin S levels by the current standard of care laboratory evaluation techniques.通过当前标准护理实验室评估技术评估血红蛋白S水平时，异咯嗪-血红蛋白复合物的影响。
Front Med (Lausanne). 2023 Apr 20;10:1149281. doi: 10.3389/fmed.2023.1149281. eCollection 2023.
5
Voxelotor use in adults with sickle cell disease in a real-world setting.在现实环境中，将voxelotor用于患有镰状细胞病的成年人。
Am J Hematol. 2022 Mar 1;97(3):E125-E128. doi: 10.1002/ajh.26453. Epub 2022 Jan 10.
6
Research in Sickle Cell Disease: From Bedside to Bench to Bedside.镰状细胞病研究：从床边到 bench 再回到床边 。
注：这里“bench”直译为“实验台”，整体表述强调了镰状细胞病研究从临床实践出发，到实验室研究，再应用回临床实践的过程 。
Hemasphere. 2021 Jun 1;5(6):e584. doi: 10.1097/HS9.0000000000000584. eCollection 2021 Jun.
7
Interactions of an Anti-Sickling Drug with Hemoglobin in Red Blood Cells from a Patient with Sickle Cell Anemia.抗镰状细胞药物与镰状细胞贫血患者红细胞中血红蛋白的相互作用。
Bioconjug Chem. 2019 Mar 20;30(3):568-571. doi: 10.1021/acs.bioconjchem.9b00130. Epub 2019 Feb 28.
8
Voxelotor treatment of a patient with sickle cell disease and very severe anemia.对一名镰状细胞病合并极重度贫血患者进行的羟基脲治疗。 （你提供的原文可能有误，推测原文为“Hydroxyurea treatment of a patient with sickle cell disease and very severe anemia.” 按照推测的原文翻译如上，若原文无误，请追问。）
Am J Hematol. 2019 Apr;94(4):E88-E90. doi: 10.1002/ajh.25389. Epub 2019 Jan 8.
本文引用的文献
1
Voxelotor (GBT440), a first-in-class hemoglobin oxygen-affinity modulator, has promising and reassuring preclinical and clinical data.伏洛托珠单抗（GBT440），一种首创的血红蛋白氧亲和力调节剂，拥有令人鼓舞且可靠的临床前和临床数据。
Am J Hematol. 2018 Mar;93(3):326-329. doi: 10.1002/ajh.25042.
2
Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin.镰状细胞血红蛋白口服生物可利用R态稳定剂GBT440的发现。
ACS Med Chem Lett. 2017 Jan 23;8(3):321-326. doi: 10.1021/acsmedchemlett.6b00491. eCollection 2017 Mar 9.
3
GBT440 Inhibits Sickling of Sickle Cell Trait Blood Under Conditions Mimicking Strenuous Exercise.GBT440在模拟剧烈运动的条件下可抑制镰状细胞性状血液的镰变。
Hematol Rep. 2016 Sep 28;8(3):6637. doi: 10.4081/hr.2016.6637.
4
New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo?抗镰状化药物的新进展：药物能否在体内直接阻止镰状血红蛋白的聚合？
Br J Haematol. 2016 Oct;175(1):24-30. doi: 10.1111/bjh.14264. Epub 2016 Sep 8.
5
GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease.在镰状细胞病小鼠模型中，GBT440可提高血红蛋白对氧的亲和力，减少镰变并延长红细胞半衰期。
Br J Haematol. 2016 Oct;175(1):141-53. doi: 10.1111/bjh.14214. Epub 2016 Jul 5.
Zotero 插件